Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jacqmin

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|August 16, 2013
Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE StudiesP Jacqmin, J R Wade, B Weatherley, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 20, 2006
Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD modelP Jacqmin, E Snoeck, E A van Schaick, et al.
Annales De La Societe Belge De Medecine Tropicale|September 1, 1995
Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseumG Pierard-Franchimont, P De Doncker, V Van de Velde, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazineE Snoeck, K Ver Donck, P Jacqmin, et al.
Antimicrobial Agents and Chemotherapy|April 4, 1998
Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and childrenL de Repentigny, J Ratelle, J M Leclerc, et al.
Renal Failure|January 1, 1990
Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory diseaseS Ibrahim, M P Derde, L Kaufman, et al.
Platelets|November 4, 2010
Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIaS G Panzer-Knodle, P Jacqmin, J D Page, et al.
Clinical Pharmacology and Therapeutics|October 6, 2016
Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPSE Monnet, G Lapeyre, E van Poelgeest, et al.
Archives of Dermatology|January 1, 1996
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazoleP De Doncker, J Decroix, G E Piérard, et al.
Clinical Pharmacology and Therapeutics|May 14, 2010
A comprehensive hepatitis C viral kinetic model explaining cureE Snoeck, P Chanu, M Lavielle, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
CPT: Pharmacometrics & Systems Pharmacology|August 16, 2013
Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE StudiesP Jacqmin, J R Wade, B Weatherley, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 20, 2006
Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD modelP Jacqmin, E Snoeck, E A van Schaick, et al.
Annales De La Societe Belge De Medecine Tropicale|September 1, 1995
Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseumG Pierard-Franchimont, P De Doncker, V Van de Velde, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 10, 1998
Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazineE Snoeck, K Ver Donck, P Jacqmin, et al.
Antimicrobial Agents and Chemotherapy|April 4, 1998
Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and childrenL de Repentigny, J Ratelle, J M Leclerc, et al.
Renal Failure|January 1, 1990
Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory diseaseS Ibrahim, M P Derde, L Kaufman, et al.
Platelets|November 4, 2010
Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIaS G Panzer-Knodle, P Jacqmin, J D Page, et al.
Clinical Pharmacology and Therapeutics|October 6, 2016
Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPSE Monnet, G Lapeyre, E van Poelgeest, et al.
Archives of Dermatology|January 1, 1996
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazoleP De Doncker, J Decroix, G E Piérard, et al.
Clinical Pharmacology and Therapeutics|May 14, 2010
A comprehensive hepatitis C viral kinetic model explaining cureE Snoeck, P Chanu, M Lavielle, et al.
Pageof 4